Who owns editorial control over the code of life? An update on CRISPR
SmPC 'carve out' limits marketing authorisation
Brexit and the life sciences sector: The UK Government's offer to the EU
Brexit and the life sciences sector: what is the relevance of the transition (implementation) period?
Brexit and the life sciences sector: guidelines for 'no deal'
Dutch competition authority ACM starts sector inquiry into anti-rheumatism drugs
作者 Bram Nijhof
Dutch Supreme Court ruling on claim interpretation in Resolution v AstraZeneca